Velcade and Rituxan Help Improve Responses in Marginal Zone Lymphoma

A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial.

Related Keywords

Junfeng Chu ,Lymphoma Society ,Pharma Companies Pull Imbruvica Indication ,Marginal Zone ,Mantle Cell ,News ,Conference ,Lymphoma Cancer ,